There is no toxicology package, no maximum tolerated dose, and no human data marking an upper limit
This in turn leads to lower production of ribofavin kinase, with a reduced activity of MTHFR and MTRR, which are critical for maintaining the activity of MethylB12
A 2025 systematic review, Vasireddi et al., HSS J 2025, screened hundreds of articles and found the BPC-157 orthopaedic base to be almost exclusively animal or low-level studies, with only isolated small human reports and no rigorous randomised trials
By Julie Bosman A look at what it takes to report on, and join, an intense fitness program at the same time
Most protocols recommend using BPC-157 for 48 weeks, though longer courses may be appropriate for chronic conditions under professional guidance
Any use outside of formally approved clinical trials falls outside the regulatory framework that governs medicines safety in the UK, meaning that individuals who obtain and use retatrutide independently do so without the quality assurance, standardised dosing oversight, and pharmacovigilance protections afforded by licensed medicines